novemb upgrad sever year
recommend share share under-perform
 previou year period
time thought share reflect neg outlook delay
gener advair restasi
environ despit reserv upgrad valuat
howev result outlook remind
valuat upgrad without clear sign thing get
better often lead stock declin valuat
off-set disappoint outlook discourag
mylan outlook appar investor well
lower estim price target
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
result miss top-line ep target largest
discrep come north american sale sale
billion well billion forecast exhibit
mylan adjust ep well year ago
guidanc low end
recent lower guidanc august look
new guidanc also well consensu ep
guidanc consensu perhap
importantli new guidanc mid-point repres declin
oppos market expect ep growth
also note guidanc rang seem wide us
swing low end high end repres swing
vs swing provid last year peer teva
increas rang guidanc lead us believ
larger swing factor play given
high end new rang consensu perhap swing
factor neg posit aggreg
compani data secur llc estim reuter
given mention undergo strateg review
state call near end
process believ may worth wait see come
process given under-perform share long
period time given new earn guidanc appear
big surpris market believ sharehold would
welcom structur manageri chang
appear us compar mylan guidanc consensu
biggest swing factor may higher sg spend
current consensu expect sg spend
approxim sale vs consensu outlook
maintain outperform rate find mani reason
downgrad share given stock after-hour
trade think market may alreadi reflect below-
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
exhibit result vs estim consensu
compani report factset secur llc estim
histori guidanc result
provid histori critic compani meet origin guidanc
new news howev rais make two point busi inher uncertain
despit rang compani guidanc previous miss guidanc consensu
forecast us found commentari futur gener optimist
perhap somewhat cautious optimist optimist nonetheless believ may led
investor believ would year earn growth given high profil approv
overal environ
move guidanc look forward deliv strong financi perform year
specif expect gener total revenu billion billion
repres year-over-year growth approxim midpoint guidanc
assum flat growth north america high single-digit growth europ rest world
bottom line expect deliv adjust ep rang
repres year-over-year growth approxim midpoint addit
look gener adjust free cash flow billion billion
mylan anthoni muro state like take moment underscor optim
excit head rajiv outlin encourag commit
reinvest busi especi area sale market
rebas guidanc incorpor best visibl around complex
product launch util assumpt resiz product opportun
remedi morgantown facil
lower previou total revenu guidanc rang billion billion
current rang billion billion roughli flat midpoint
result lower top line expect also revis adjust ep guidanc
rang per share previou rang share
new adjust ep rang repres increas midpoint compar
said remain commit full year guidanc provid august
confirm depend singl product approv launch north america
busi predominantli gener benefit broad mix dosag
form well beyond oral solid see continu stabil price environ
year-to-d launch nearli new product north america two-third
inject
report adjust ep vs consensu sale billion
modestli consensu billion billion estim adjust gross
margin approxim in-line consensu forecast
expens million well million estim consensu
million sg expens million in-line million estim
consensu million
segment level north america disappoint worth point europ
rest world larg in-line model dont think busi fall
gener adjust approxim billion vs billion
put ep histori context believ spent signific amount money
acquisit describ accret adjust ep trend sinc
note acquisit expect immedi accret approxim million
acquir immedi accret topic busi acquir meda billion deal
provid signific accret adjust earn per share ep
complet billion share buy-back acquir tobi million ep
believ earn progress guidanc encourag especi given
acquisit period
detail guidanc
provid guidanc revenu billion consensu billion
larg rang ep vs consensu call ceo heather bresch indic
guidanc rang reflect volatil seen marketplac think
tri respect volatil take kind everyth consider
spend side thing perplex us late februari provid rang million
capit expenditur reflect wide rang invest consider differ
spend million vs spend million capit expenditur larg one would suspect
precis number would known two month year similarli larg increas sg
spend perplex sure use also larg increas
compani report factset secur llc
highmidpointconsensustot gross sg net specialti pharmaceut
factset secur llc estim
million unless otherwis note
compani report secur llc estim
price target
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like continu challeng
gener drug penetr may alreadi peak epipen concentr sale profit
govern risk sec investig lawsuit integr risk tie meda deal
believ share posit near-term out-performance driven larg discount
estim fair valu still cautiou outlook gener fundament like
stock current valuat believ may alreadi reflect consensu outlook
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
